


In vivo ^{13}C -MRI using SAMBADENA

S5 Fig



S5 Fig: *In vitro* MRI with SAMBADENA-produced tracer solution. The phantom was mounted to the setup as described in S4 Fig and an HP experiment was performed ($c_{\text{HEA}} = 5 \text{ mM}$, $c_{\text{cat}} = 1 \text{ mM}$, $t_{\text{hyd}} = 5 \text{ s}$, $80 \text{ }^\circ\text{C}$, $15 \text{ bar } p\text{H}_2$). The tracer was extracted from the reactor and $150\mu\text{l}$ were injected into the phantom, similarly to the *in vivo* experiment described in the main text. Subsequently, ^{13}C -MRI was acquired ((a), co-registered with an ^1H -MRI (b), which depicted the tracer solution in the tube of the phantom (see S4 Fig) (c). Note that in contrast to *in vivo* experiments, ^{13}C was recorded using a ^{13}C -surface coil (S2 Fig). Both, ^1H - and ^{13}C -MRI were normalized to the highest signal in the image. A 5 mM tracer solution was chosen because concentration and magnetization are similar to *in vivo* experiments ($300\mu\text{l}$, 80 mM tracer dilute with $\sim 2.1 \text{ ml}$ blood of a 30 g mouse and yield a final tracer concentration of $\sim 10 \text{ mM}$ *in vivo*; additionally, as HP of a concentrated sample is lower (see Supplementary Information 1), a $2 \times$ lower concentration was chosen). ^{13}C -MRI: $90/180^\circ$, RARE-factor: 38, FOV: $(8.4 \text{ cm})^2$, acquisition matrix of $128 \times 96 \text{ px}$, interpolated to $256 \times 256 \text{ px}$, in-plane resolution: $0.33 \times 0.33 \text{ mm}$, one slice with thickness: 6 cm , $T_{\text{R}} = 0.487 \text{ s}$, $T_{\text{E}} = 79 \text{ ms}$, acquisition time: 0.487 s .